• Shop
  • Shopping cart
  • Contact Waters
  •  United States
    • China / 简体中文
    • Japan / 日本語
    • India / English
    • United Kingdom / English
    • Germany / Deutsch
    • France / Français
    • South Korea / 한국어
    • Canada / Français
    • Canada / English
    • Taiwan / 繁體中文
    • Brazil / Português
    • Italy / Italiano
    • Spain / Español
    • More...

Innovator and Biosimilar Infliximab: Comparability Assessment of the Host Cell Proteins and Protein Higher Order Structure

Library Number:
PSTR134883561
Author(s):
Catalin Doneanu, Jing Fang, Alain Beck, Weibin Chen and Ying Qing Yu
Source:
Waters
Content Type:
Posters
Content Subtype:
WCBP
Related Products:
SYNAPT G2-S HDMS
 
Host Cell Proteins (HCPs)
 
Biosimilars
 
ACQUITY UPLC M-Class System with HDX Technology
 
ACQUITY UPLC M-Class System with 2D Technology
Abstract / Summary

This study shows comparability analysis between a biosimilar product and an innovator mAb in both Host Cell Protein (HCP) and higher order structure level. Both studies were carried out using a micro flow ACQUITY UPLC system interfaced to a high resolution mass spectrometry (Synapt HDMS). The HCP study concludes that two HCPs (epidermal growth‐factor like protein 8 and WD repeat containing protein 37) were found in both the innovator and the biosimilar mAbs, however, the biosimilar mAb has higher level of HCP compare to the innovator (2‐4 fold higher). Protein tertiary structure analysis was conducted using Hydrogen Deuterium Exchange Mass Spectrometry (HDX MS), results showed the conformation for both mAbs are highly comparable except a minute difference in CH2 domain. Our study shows great promise in adapting these analytical capabilities into biosimilar drug development process.


Downloadable File(s)
Title Format File Size
Download PDF PDF 1937.21kB